Panagora Asset Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Panagora Asset Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-964	Closed	-$136K	–	2518
2021 Q2	$136K	Hold	964	–	–	﹤0.01%	1774
2021 Q1	$96K	Buy	+964	New	+$112K	﹤0.01%	2029
2018 Q4	–	Sell	-12,443	Closed	-$1.02M	–	2549
2018 Q3	$1.02M	Buy	+12,443	New	+$877K	﹤0.01%	1121
2018 Q1	–	Sell	-7,693	Closed	-$218K	–	2420
2017 Q4	$218K	Buy	+7,693	New	+$215K	﹤0.01%	1643

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Panagora Asset Management's RETA Position: Q3 2021 in Review

Panagora Asset Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2021, closing a stake of 964 shares — an estimated $136K sold.

Panagora Asset Management first reported a position in RETA in Q4 2017 and held it in 4 quarters. The position peaked at $1.02M in Q3 2018. 181 funds tracked by Wall St. Rank hold RETA as of Q3 2021.

Panagora Asset Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2021 after selling out during the quarter.
Panagora Asset Management sold 964 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2021, an estimated $136K.
Panagora Asset Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 4 quarters.
Panagora Asset Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.02M in Q3 2018.
181 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.